Document Detail

Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon-alpha (IFN-alpha) therapy.
MedLine Citation:
PMID:  7497436     Owner:  NLM     Status:  MEDLINE    
Cytogenetic analysis is considered pivotal for assessing the remission rate in CML patients on IFN therapy. On the basis of general agreement, at least 25 metaphases should be analyzed in each case. The main limitations to this approach are: 1) the small number of analyzable metaphases generally found in cytogenetic preparations from IFN-alpha-treated patients; and 2) the inability of this technique for scoring interphase cells. We compared the results of cytogenetic analysis and double-color FISH detection of bcr/abl genes fusion in 13 CML patients on IFN-alpha therapy (marrow sampling for cytogenetic and FISH analysis was carried out after 12 months in all patients and repeated after 18 months of IFN therapy in patients 4, 6, and 8). In five specimens, 20 to 25 cells were evaluable for cytogenetic examination, in another five no analyzable metaphases were scored, and in the remaining six samples two to 14 cells could be analyzed. With FISH detection at least 100 cells were easily scored in each specimen (mean number, 175). Comparing the results carried out with the two methods in different samples it emerged that cytogenetic analysis led to improper conclusions as regards the rate of Ph positivity, even in those patients where 20-25 metaphases were analyzed. Although many more cases have to be studied to establish the role of FISH analysis in Ph-positive patients, we are of the opinion that cytogenetic analysis is unfit for easily and accurately assessing the actual quality of remission in IFN-treated subjects.
M C Cox-Froncillo; M Cantonetti; M Masi; R Lentini; P Giudiceandrea; L Maffei; M Tribalto; S Amadori; G Papa
Related Documents :
9375746 - Clinical relevance of t-cell receptor delta gene rearrangements in childhood b-precurso...
3460626 - Prediction of response of patients with acute nonlymphocytic leukaemia to remission ind...
15075086 - Molecular monitoring to identify a threshold of cbfbeta/myh11 transcript below which co...
19784076 - Multicenter validation study of a transplantation-specific cytogenetics grouping scheme...
22155116 - Racial and ethnic disparities in the use of intravenous recombinant tissue plasminogen ...
22147006 - Clinical features of adult patients with secondary hemophagocytic lymphohistiocytosis f...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer genetics and cytogenetics     Volume:  84     ISSN:  0165-4608     ISO Abbreviation:  Cancer Genet. Cytogenet.     Publication Date:  1995 Oct 
Date Detail:
Created Date:  1996-01-17     Completed Date:  1996-01-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7909240     Medline TA:  Cancer Genet Cytogenet     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  15-8     Citation Subset:  IM    
Division of Hematology, Tor Vergata University, Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Chromosome Aberrations*
In Situ Hybridization, Fluorescence
Interferon-alpha / therapeutic use*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*,  therapy
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cytogenetics of malignant gliomas: I. The autosomes with reference to rearrangements.
Next Document:  Partial triplication (7q) in a child with acute lymphoblastic leukemia demonstrated with conventiona...